Drugs / GSK364735
GSK364735
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00386347 | Oct 2006 → ? | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00398125 | Nov 2006 → Apr 2007 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK364735 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00386347 ↗ |
| Known as | S-364735 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256978 ↗ |
| Known as | S/GSK 364735 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256978 ↗ |
| Modality | Small molecule | — CHEMBL1256978 ↗ |
| Route | Oral | “GSK364735 oral solution and oral tablets” NCT00386347 ↗ |